FICHIT

Je m'inscris

QUANTUM GENOMICS

0/5 (0 note(s))
Note donnée : aucune
Paris
47
Specialized in cardiovascular diseases. It is developing a new class of centrally acting drugs, called Brain Aminopeptidase A Inhibitors (BAPAIs), for the treatment of complicated/resistant hypertension and heart failure.
The most advanced product is QGC001, a first in class antihypertensive drug-candidate for monotherapy, which started phase IIa at the beginning of 2015. More than 50% of patients have been recruited as of September 2015 and this clinical trial should be completed by June 2016.

QGC001 inhibits an enzyme in the brain, generating a triple mechanism of action:

- Reduction of vasopressin release, which increases the diuresis
- Decrease of the sympathetic nerve activity, which lowers vascular resistance
- Increase of the baroreflex, which controls heart rate
Each of these actions contributes to the reduction of blood pressure.
SEGARD Lionel
www.quantum-genomics.com
ALQGC:FP

Fiche créée le 10/04/2016 par Guillaume   vue 6 fois.